Aparicio-Siegmund, Samadhi, Garbers, Yvonne, Flynn, Charlotte M., Waetzig, Georg H., Gouni-Berthold, Ioanna, Krone, Wilhelm, Berthold, Heiner K., Laudes, Matthias, Rose-John, Stefan and Garbers, Christoph ORCID: 0000-0003-4939-6950 (2019). The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes. Am. J. Physiol.-Endocrinol. Metab., 317 (2). S. E411 - 10. BETHESDA: AMER PHYSIOLOGICAL SOC. ISSN 1522-1555
Full text not available from this repository.Abstract
Serum levels of interleukin-6 (IL-6) are increased in patients with type 2 diabetes (T2D). IL-6 exerts its pleiotropic effects via the IL-6 alpha-receptor (IL-6R). which exists in membrane-bound and soluble (sIL-6R) forms and activates cells via the beta-receptor glycoprotein 130 (gp130). The nonsynonymous single-nucleotide polymorphism (SNP) rs2228145 (Asp358AIa) within the IL6R locus is associated with T2D. The aim of this study was to determine whether sIL-6R in combination with soluble gp130 (sgp130) is able to form an IL-6-neutralizing buffer in healthy subjects and whether this is disturbed in T2D. We found that sIL-6R-sgp130 indeed forms an IL-6-neutralizing buffer in the serum of healthy humans, whose capacity is controlled by the SNP of the IL-6R. Circulating sIL-6R-sgp130 levels were lower in T2D subjects (P < 0.001), whereas IL-6 was high and inversely correlated with sIL-6R (r = -0.57, P < 0.001), indicating a severe disturbance of the buffer. This phenomenon is also observed in sex- and age-matched patients with both T2D and atherosclerosis but not in patients with atherosclerosis alone. In conclusion, sIL-6R and sgp130 serum levels were significantly lower in T2D patients compared with healthy subjects or atherosclerosis patients, although IL-6 levels were high. These data suggest that disturbance of the protective buffer may be closely associated with T2D pathophysiology.
Item Type: | Journal Article | ||||||||||||||||||||||||||||||||||||||||||||
Creators: |
|
||||||||||||||||||||||||||||||||||||||||||||
URN: | urn:nbn:de:hbz:38-145436 | ||||||||||||||||||||||||||||||||||||||||||||
DOI: | 10.1152/ajpendo.00166.2019 | ||||||||||||||||||||||||||||||||||||||||||||
Journal or Publication Title: | Am. J. Physiol.-Endocrinol. Metab. | ||||||||||||||||||||||||||||||||||||||||||||
Volume: | 317 | ||||||||||||||||||||||||||||||||||||||||||||
Number: | 2 | ||||||||||||||||||||||||||||||||||||||||||||
Page Range: | S. E411 - 10 | ||||||||||||||||||||||||||||||||||||||||||||
Date: | 2019 | ||||||||||||||||||||||||||||||||||||||||||||
Publisher: | AMER PHYSIOLOGICAL SOC | ||||||||||||||||||||||||||||||||||||||||||||
Place of Publication: | BETHESDA | ||||||||||||||||||||||||||||||||||||||||||||
ISSN: | 1522-1555 | ||||||||||||||||||||||||||||||||||||||||||||
Language: | English | ||||||||||||||||||||||||||||||||||||||||||||
Faculty: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||
Divisions: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||
Subjects: | no entry | ||||||||||||||||||||||||||||||||||||||||||||
Uncontrolled Keywords: |
|
||||||||||||||||||||||||||||||||||||||||||||
Refereed: | Yes | ||||||||||||||||||||||||||||||||||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/14543 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |